Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after b
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... in which babies are born can have a dramatic ... That is the conclusion of a new study published ... Neuroscience . The experiment provides the first evidence for ... conducted by Professor of Biological Sciences Douglas McMahon, graduate ...
... for the first time that exactly how we see our environment ... We are all familiar with the idea that our thoughts ... assume that how we perceive the visual world is usually very ... the area at the back of the brain responsible for processing ...
... reversed by activating stem cells that can repair injury in ... from the Universities of Cambridge and Edinburgh have identified a ... sheaths that protect nerve fibres in the brain. ... can be exploited to make the brain,s own stem cells ...
Cached Biology News:Babies' biological clocks dramatically affected by birth light cycle 2Babies' biological clocks dramatically affected by birth light cycle 3Babies' biological clocks dramatically affected by birth light cycle 4Babies' biological clocks dramatically affected by birth light cycle 5Seeing the world differently 2Study reveals new possibility of reversing damage caused by MS 2
(Date:4/20/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... reflecting Lilly,s diverse oncology pipeline, during the American Association ... 18-22 in Philadelphia , Pa.  ... theme of this year,s AACR meeting and one that ... of therapies that accelerate the pace and progress of ...
(Date:4/20/2015)... NEW DELHI , April 20, 2015 ... a PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform ... AM EST  -  Supramolecular Assembly of ... as Cytotoxic Payload - Presented on Sunday, Apr 19, ... a leader in supramolecular therapeutic program, today announced that ...
(Date:4/20/2015)... -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider ... financial results for the fourth quarter and full year ... Financial Highlights(Compared to the fourth quarter 2013) , ... 11.4% from $22.9 million in the prior year period. ... influenza vaccine of $0.1 million in the fourth quarter ...
(Date:4/20/2015)... April 20, 2015 Global Stem ... Aesthetic Meeting 2015, an annual gathering of aesthetic medicine ... M.D., is scheduled to introduce the company’s brand new ... with adipose-derived stem cell techniques. , The course ... patients in the aesthetic field, including facial aging caused ...
Breaking Biology Technology:Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3
... are not teaching skills needed for the Information Age. Their ... that we are way beyond the Industrial Age. , ... Rs. I am not talking about reading, writing and `rithmetic; ... these add up to regimentation, which is what was needed ...
... CleanTech Partners will receive $1.5 million from the ... attempt to produce cellulosic ethanol at paper mills by extracting ... paper making. , ,Masood Akhtar, president of CleanTech Partners and ... for the grant. Other participants included the United ...
... Wis. - The origins of Madison's technology industry can ... pretty isolated when he opened DNASTAR, Inc . that year. ... Promega - and a few more, the producer of DNA ... an era where it was considered bad form - even a ...
Cached Biology Technology:Rote education fails the Information Age 2Rote education fails the Information Age 3Rote education fails the Information Age 4DNASTAR catches second wave of sequencing 2DNASTAR catches second wave of sequencing 3DNASTAR catches second wave of sequencing 4
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
...
...
...
Biology Products: